金斯瑞(01548.HK):鎮江檢察院不對前董事及附屬等提訴訟
金斯瑞生物科技(01548.HK)公佈,有關中國鎮江海關緝私部門對關於涉嫌違反中國法律關於進出口規定的調查,公司前董事、前董事長兼首席執行官、傳奇生物科技(LEGN.US)前董事、前董事長兼首席執行官章方良,與公司間接全資附屬南京金斯瑞生物科技及江蘇金斯瑞生物科技,以及曾處理集團進出口活動的三名僱員和一名前僱員,已獲鎮江市人民檢察院通知,調查已審查完畢,檢察院決定不對任何單位或個人提起任何訴訟。
據公司中國法律顧問的意見,決定意味着任何起訴程序及相關審查現已結束,公司及其任何附屬、章方良或任何上述僱員及前僱員均沒有或不會就調查承擔任何刑事責任。目前,集團業務營運維持正常。
此外,公司再委任章方良爲非執行董事,自昨日(5日)起生效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.